lipid nanoparticles

Overview

Lipid nanoparticles (LNPs) are nanoscale delivery vehicles composed of ionizable or cationic lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipid conjugates, engineered to encapsulate and deliver nucleic acid therapeutics — including small interfering RNA (siRNA), messenger RNA (mRNA), and CRISPR-Cas genome editing machinery — into target cells. Their core mechanism relies on ionizable lipids that carry a net positive charge at the low pH of endosomes, facilitating membrane disruption and endosomal escape following cellular uptake, thereby releasing their cargo into the cytoplasm. LNPs gained landmark clinical validation with the approval of patisiran (Onpattro) for RNA interference therapy and the mRNA-based COVID-19 vaccines, establishing them as the preeminent non-viral nucleic acid delivery platform in modern medicine.

The biological significance of LNPs stems from their versatility, biocompatibility, and capacity for chemical programmability. Their composition — particularly the identity and molar ratio of ionizable lipids, helper lipids, and PEG-lipids — governs key pharmacological properties including organ tropism, cellular specificity, endosomal escape efficiency, immunogenicity, and cargo protection from nuclease degradation. While early LNP formulations exhibited a strong liver tropism driven by apolipoprotein E adsorption and hepatic clearance mechanisms, contemporary research is intensively focused on engineering extrahepatic targeting toward tissues such as the lung, spleen, heart, retina, and colon, broadening the therapeutic reach of nucleic acid medicines across a wide spectrum of diseases including cardiovascular disease, cancer, metabolic disorders, and inflammatory conditions.

Focus of Latest Publications

Recent literature reflects a rapidly expanding scope for LNP-mediated nucleic acid delivery, with studies pushing boundaries across therapeutic area, target organ, and cargo type.

Extrahepatic and Targeted Delivery

A central challenge highlighted across multiple 2026 publications is overcoming liver tropism to achieve extrahepatic delivery. One study in ACS Nano (PMID: 42160160) developed a post-conjugation process for attaching antibodies to the LNP surface at tunable densities, enabling selective RNA delivery to non-hepatic target cells. Separately, a study in Small (PMID: 41913646) reported a purely water-based, organic solvent-free LNP formulation that preserved delivery efficiency while improving reproducibility and reducing manufacturing complexity — a formulation designed with extrahepatic applications in mind. Research published in Nature Biomedical Engineering (PMID: 41845088) synthesized and evaluated 444 lung-targeting (LuT) lipids, identifying candidates that form LNPs capable of efficiently delivering mRNA and CRISPR-Cas9 genome editors to lungs with minimal off-target effects. For ocular delivery, a study in Journal of Controlled Release (PMID: 41786044) compared LNP formulations incorporating ionizable lipids SM102 and MC3 for intravitreal delivery of LATS1 mRNA as a strategy against uveal melanoma. Retinal delivery was also addressed in Molecular Pharmaceutics (PMID: 41931102), where formulation screening identified LNPs optimized for mRNA delivery to the retina.

cancer immunotherapy and tumor microenvironment Remodeling

LNPs are playing an increasingly prominent role in cancer immunotherapy through reprogramming of the tumor microenvironment. A study in Nature Biotechnology (PMID: 42129506) used LNPs to deliver immune-remodeling mRNAs (IR-mRNAs) encoding NF-κB-inducing kinase (NIK) and interferon regulatory factor 8 (IRF8) to dendritic cells within the tumor microenvironment, generating durable antitumor immunity across multiple cancer models. A complementary platform published in Advanced Science (PMID: 42080357) introduced a nanobody-conjugated LNP system targeting dendritic cells for active relicensing in cancer immunotherapy. For ovarian cancer, a study in Journal of Nanobiotechnology (PMID: 42116169) described an intraperitoneal mRNA-based immunotherapy encapsulating a combination of cytokines — including IL-12, IL-15, pro-IL-18, and Caspase-1 (CASP1) — in LNPs to reprogram the immunosuppressive tumor microenvironment in a syngeneic ID8 mouse model. LNP delivery of mRNA encoding anti-HTRA1 antibodies was explored in Bioconjugate Chemistry (PMID: 42120973) for pancreatic ductal adenocarcinoma, suppressing HTRA1/HIF-1 signaling to improve the redox tumor microenvironment.

In Vivo CAR T Cell Engineering

Several publications describe LNPs as delivery vehicles for in vivo generation of chimeric antigen receptor T (CAR-T) cells, circumventing the complexity of ex vivo manufacturing. A study in ACS Nano (PMID: 42130331) reported beta-hydroxy thioether-derived ionizable lipids forming spleen-tropic LNPs capable of delivering nucleic acids to engineer CD19 chimeric antigen receptor T (CAR-T) cells in vivo, positioning this as a therapeutic strategy across a broad spectrum of malignant diseases. Reviews in HemaSphere (PMID: 42064385) and Cancer Research (PMID: 41490421) surveyed the LNP-based delivery landscape for in vivo CAR therapy, contrasting LNPs with lentiviral vectors and polymer-based non-viral systems.

Gene Editing and CRISPR Delivery

The combination of LNPs with CRISPR-Cas technologies represents one of the most active frontiers. A 2026 American College of Cardiology Scientific Statement (JACC, PMID: 41885675) identified LNPs as a promising approach for cardiovascular disease gene editing, particularly for hepatocyte-expressed therapeutic targets. A study in PNAS (PMID: 42150080) screened a chemically diverse LNP library against human cardiomyocytes, identifying the lead formulation 18:1 TAP10 for potent cardiac transfection capable of enabling in vivo cardiac gene editing. For Alzheimer's disease, a review in Acta Neurologica Belgica (PMID: 41931258) highlighted LNPs alongside adeno-associated viral vectors and lentiviral systems as delivery platforms for CRISPR-Cas9-based interventions targeting pathways associated with Beta amyloid and microtubule associated protein tau. LNPs were also assessed in Critical Reviews in Oncology/Hematology (PMID: 41833894) as part of a broader non-viral toolkit for CRISPR-mediated cancer therapies, alongside gold nanoparticles and stimuli-responsive systems.

Therapeutic siRNA Delivery

Multiple studies demonstrated LNP-delivered siRNA for silencing disease-relevant targets. In Blood (PMID: 41632828), siRNA targeting PSMD1 — a proteasome subunit identified as a key therapeutic target in multiple myeloma — was delivered via LNPs, reducing tumor growth in cell lines and primary patient samples while sparing normal cells. For diabetes mellitus-induced erectile dysfunction, a study in Advanced Science (PMID: 42085610) developed siRNA against Zdhhc9 encapsulated in LNPs, suppressing ZDHHC9-mediated palmitoylation of ACSL4, a driver of ferroptosis, in the corpus cavernosum. LNP-delivered siRNA against a mitochondrial tRNA-derived small RNA (mt-5'tiRNA-34-GlnTTG) was explored in Cancer Letters (PMID: 41707977) to inhibit vascular invasion in lung adenocarcinoma.

mRNA Therapeutics Beyond Vaccines

LNPs were evaluated across a wide range of mRNA therapeutic contexts. For Gaucher disease, a study in Biochemical and Biophysical Research Communications (PMID: 41855860) demonstrated that a single administration of human glucocerebrosidase (hGBA1)-encoding mRNA in LNPs produced detectable enzyme activity in the liver and spleen of mice within 72 hours. For inflammatory conditions, a study in Biomaterials (PMID: 41317703) showed that LNPs delivering IL-4 mRNA to primary macrophages induced rapid transfection, IL-4 secretion, and reparative phenotype modulation — demonstrating potential in inflammatory injuries. mRNA-LNPs were also applied intracolonically in Inflammation Research (PMID: 42154259) to generate epithelial cells with enhanced efferocytic capacity, attenuating intestinal inflammation including colitis in mice.

Surface Engineering and Biodistribution Control

Surface chemistry modifications continue to refine LNP tropism and safety. A study in ACS Applied Materials & Interfaces (PMID: 42117531) engineered LNP surfaces with heparosan polysaccharides, demonstrating safe and effective mRNA delivery in vitro and in vivo. Research in ACS Nano (PMID: 41989838) systematically examined how glycan chemical structures — attached to LNP surfaces — dictate organ- and cell-specific tropism and modulate immune responses. Biomimetic LNP strategies were reported in the Journal of Colloid and Interface Science (PMID: 41610521) to enhance delivery to breast cancer microenvironment cells via homotypic and heterotypic adhesion mechanisms.

Formulation Science and Manufacturing

The optimization of LNP formulations received dedicated attention. A study in Drug Delivery and Translational Research (PMID: 42149348) critically examined the dominance of inherited lipid ratios in LNP development, comparing one-factor-at-a-time (OFAT) with Design of Experiments (DoE) approaches and demonstrating that DoE better captures the combined influence of composition and process parameters. Manufacturing was advanced by a study in Journal of Controlled Release (PMID: 41791459) reporting an oscillation-generating micromixing (FDmiX) technique as a scalable, high-throughput alternative to conventional microfluidic mixing for mRNA-LNP production. For pulmonary delivery, a functional lyoprotectant platform reported in Journal of Controlled Release (PMID: 41780686) addressed LNP instability in liquid formulations by enabling storage-stable, freeze-dried LNPs capable of penetrating pathological mucus in chronic airway disease models. artificial intelligence and machine learning are increasingly integrated into formulation development, with a review in Advanced Drug Delivery Reviews (PMID: 41579967) cataloguing AI-guided optimization of LNP design as a paradigm for accelerating formulation discovery and reducing experimental burden.

Agricultural and Analytical Applications

Beyond mammalian therapeutics, a study in Scientific Reports (PMID: 42129408) explored polydiallyldimethylammonium chloride (poly(DADMAC))-incorporated LNPs for delivering antimicrobial Peptides into plant cells via foliar application, extending the LNP delivery concept to plant biology. On the analytical side, a study in Analytical and Bioanalytical Chemistry (PMID: 42135550) developed LC-HRMS detection methods for three ionizable lipids in equine plasma as surrogate markers for long-term LNP-mediated gene-doping surveillance, addressing emerging regulatory concerns in sports medicine.

Key Publications

• Jun mRNA Vaccines for Influenza: Hope for a Universal Vaccine? (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026, PMID 42295617): "Messenger RNA (mRNA)-formulated lipid-nanoparticles have evolved from an emergency pandemic vaccine experiment into a versatile vaccine platform."
• May Post-Conjugation Process for Antibody-Conjugated Lipid Nanoparticles Enabling Tunable Antibody Surface Density for Targeted RNA Delivery. (ACS nano, 2026, PMID 42160160): "Lipid nanoparticles (LNPs) are established nonviral carriers for RNA therapeutics; however, extrahepatic targeting remains challenging due to liver tropism."
• May A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42150080): "By screening a chemically diverse LNP library, we identified a lead LNP, 18:1 TAP10, with potent human cardiac transfection capability."
• May In vivo colonic epithelial cell editing attenuates intestinal inflammation in mice. (Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026, PMID 42154259): "Here, we developed a therapeutic approach to generate epithelial cells with enhanced efferocytic capacity in vivo by delivering mRNA in lipid nanoparticles (LNPs)."
• May Revisiting the lipid ratio in lipid nanoparticles: A comparison of OFAT and design of experiments approaches. (Drug delivery and translational research, 2026, PMID 42149348): "Despite the clinical success of lipid nanoparticles (LNPs), formulation optimisation remains dominated by inherited lipid ratios and screening approaches that fail to capture the combined influence of composition and manufacturing process."
• May LC-HRMS detection of three ionizable lipids in equine plasma: surrogate markers for long-term LNP-mediated gene-doping surveillance. (Analytical and bioanalytical chemistry, 2026, PMID 42135550): "Lipid nanoparticles (LNPs) are essential delivery vehicles for messenger ribonucleic acid (mRNA)-based therapies."
• May Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma. (Blood, 2026, PMID 41632828): "Targeting PSMD1 with small interfering RNA (siRNA), delivered via lipid nanoparticles (LNPs), reduced tumor growth in MM cell lines and primary patient samples while sparing normal cells."
• May β-Hydroxy Thioether-Derived Ionizable Lipids for Spleen-Tropic mRNA Delivery and In Vivo Chimeric Antigen Receptor T Cell Engineering. (ACS nano, 2026, PMID 42130331): "The delivery of nucleic acids via lipid nanoparticles (LNPs) to generate chimeric antigen receptor (CAR) T cells in vivo represents a promising therapeutic strategy for a broad spectrum of diseases."
• May Poly(DADMAC) incorporated lipid nanoparticles enhance the delivery of antimicrobial peptides into plant cells. (Scientific reports, 2026, PMID 42129408): "This study proposes Polydiallyldimethylammonium chloride (poly(DADMAC)) incorporated lipid nanoparticles as a potential method to deliver the drugs into the plant vascular system via foliar application."
• May Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. (Nature biotechnology, 2026, PMID 42129506): "Here we engineer immune cells in the tumor microenvironment using lipid nanoparticles (LNPs) to deliver immune-remodeling mRNAs (IR-mRNAs) encoding NF-κB-inducing kinase or interferon regulatory factor 8."